CINECA IRIS Institutional Research Information System

BRUNETTO, MAURIZIA ROSSANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.019
AS - Asia 15.049
EU - Europa 8.019
SA - Sud America 2.804
AF - Africa 412
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 12
Totale 55.341
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.138
SG - Singapore 4.450
CN - Cina 4.208
HK - Hong Kong 2.971
BR - Brasile 2.285
IT - Italia 1.956
VN - Vietnam 1.363
SE - Svezia 1.194
BG - Bulgaria 1.039
DE - Germania 702
CA - Canada 668
FR - Francia 636
RU - Federazione Russa 534
KR - Corea 519
UA - Ucraina 459
GB - Regno Unito 420
FI - Finlandia 370
TR - Turchia 358
IN - India 247
CH - Svizzera 204
AR - Argentina 200
AT - Austria 170
JP - Giappone 160
BD - Bangladesh 141
MX - Messico 100
ID - Indonesia 92
EC - Ecuador 87
IQ - Iraq 87
ZA - Sudafrica 85
PK - Pakistan 76
CI - Costa d'Avorio 71
NL - Olanda 68
CO - Colombia 59
SA - Arabia Saudita 45
MA - Marocco 44
VE - Venezuela 42
UZ - Uzbekistan 41
EG - Egitto 40
BE - Belgio 39
ES - Italia 38
PH - Filippine 36
CL - Cile 34
PY - Paraguay 33
MY - Malesia 32
PL - Polonia 31
SN - Senegal 27
KE - Kenya 26
TN - Tunisia 25
PE - Perù 24
AE - Emirati Arabi Uniti 23
BJ - Benin 22
JM - Giamaica 21
NP - Nepal 20
RO - Romania 20
UY - Uruguay 20
AU - Australia 19
CZ - Repubblica Ceca 19
JO - Giordania 19
TW - Taiwan 19
DZ - Algeria 18
IE - Irlanda 18
KZ - Kazakistan 18
NG - Nigeria 18
TT - Trinidad e Tobago 18
BO - Bolivia 16
GR - Grecia 16
IR - Iran 15
TH - Thailandia 15
AL - Albania 14
CR - Costa Rica 12
ET - Etiopia 12
OM - Oman 12
AZ - Azerbaigian 11
HU - Ungheria 11
IL - Israele 11
HN - Honduras 9
LT - Lituania 9
DO - Repubblica Dominicana 8
LB - Libano 8
PA - Panama 8
DK - Danimarca 7
KG - Kirghizistan 7
NI - Nicaragua 7
PT - Portogallo 7
RS - Serbia 7
XK - ???statistics.table.value.countryCode.XK??? 7
GE - Georgia 6
GT - Guatemala 6
SY - Repubblica araba siriana 6
BA - Bosnia-Erzegovina 5
EU - Europa 5
NZ - Nuova Zelanda 5
QA - Qatar 5
BB - Barbados 4
BY - Bielorussia 4
LK - Sri Lanka 4
MD - Moldavia 4
MN - Mongolia 4
MR - Mauritania 4
SV - El Salvador 4
Totale 55.261
Salva come PNG Salva come JPEG
Città #
Fairfield 3.088
Woodbridge 3.056
Ashburn 3.003
Hong Kong 2.946
Singapore 2.448
Ann Arbor 1.809
Houston 1.762
Dallas 1.436
San Jose 1.338
Seattle 1.247
Sofia 1.036
Cambridge 1.011
Wilmington 974
Chandler 946
Santa Clara 892
Shanghai 892
Beijing 767
New York 743
Hefei 709
Milan 688
Jacksonville 578
Ottawa 562
Seoul 508
Boardman 503
Princeton 440
Lawrence 431
Lauterbourg 377
Medford 355
Ho Chi Minh City 337
Des Moines 332
Los Angeles 289
Nanjing 274
Council Bluffs 230
Hanoi 209
Istanbul 193
Frankfurt am Main 185
Bern 178
Buffalo 174
San Diego 171
Dearborn 160
Redondo Beach 159
São Paulo 156
Dong Ket 152
Tokyo 133
Vienna 128
Nanchang 125
Izmir 108
Jüchen 100
Munich 99
Pisa 98
Serra 91
Helsinki 88
Chicago 81
Rio de Janeiro 80
Kunming 79
London 79
Ogden 78
Florence 76
Nuremberg 71
Abidjan 70
Shenyang 68
Changsha 67
Rome 66
Turku 66
Belo Horizonte 60
Da Nang 52
Hebei 51
Brasília 49
Redwood City 48
Washington 43
Jiaxing 42
Norwalk 41
Tianjin 41
Boulder 40
Tashkent 40
Paris 39
Curitiba 35
Salvador 35
Columbus 34
Pune 34
Johannesburg 33
San Francisco 31
Baghdad 30
Campinas 30
Dhaka 30
Porto Alegre 30
Brooklyn 29
Guangzhou 29
Jinan 29
Montreal 29
The Dalles 29
Brussels 28
Lucca 28
Orem 28
Quito 28
Haiphong 27
Lancaster 27
Toronto 27
Dakar 26
Guayaquil 26
Totale 40.853
Salva come PNG Salva come JPEG
Nome #
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study 260
Active HBV replication in HBsAg carriers with chronic Delta infection 248
Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound 227
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 227
Development of a liver model using PAM scaffolds in static and dynamic conditions 226
Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen 223
Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen 218
REPLICATING AND VIRION SECRETING HEPATITIS B MUTANT VIRUS UNABLE TO PRODUCE PRES2 PROTEIN 205
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment 205
Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D 204
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B 202
Sequence variation in hepatitis C viral isolates 202
A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease 200
T-lymphocyte response to hepatitis C virus in different clinical courses of infection 197
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations 196
A multiphase model of th dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alfa2a, lamivudine and combination therapy 196
Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? 194
Hepatitis delta virus, a model of liver cell pathology 193
A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers 192
Liver stiffness, a non-invasive marker of liver disease in the HBV carrier 189
The natural history of chronic delta hepatitis 188
Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization 188
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases 188
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 188
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview 186
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study 186
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging 186
Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children 185
Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research 185
High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders 184
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with graves’ ophthalmopathy 184
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers 183
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values 182
Severe liver injury possibly due to verapamil 181
Variants of hepatitis B virus 181
Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B 181
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study 179
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 179
Hepatitis B virus unable to secrete e antigen 177
Possible immunopathogenesis for fibrosing cholestatic hepatitis 177
Hepatitis C virus infection in type II essential mixed cryoglobulinemias 177
Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects 177
Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin 176
Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study 174
Multicenter evaluation of the elecsys hepatitis B surface antigen quantitative assay 174
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C 173
Software and expert system for the management of chronic hepatitis B 173
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease 173
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection 172
Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay 172
Rapidly progressive HBsAg hepatitis in Italy: a syndrome of Delta hepatitis virus superinfection 171
Characterization of hepatitis delta antigen gene of a highly pathogenic strain of hepatitis delta virus 171
Asymptomatic hypermylasemia and hyperlipasemia associated with aripiprazole 171
Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C 171
Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey 170
Hepatitis B virus surface antigen levels: a guide to sustained response to Peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 170
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 169
A dynamic analysis of IgM anti-HCV helps to distinguish hepatitis C from acute rejection in liver transplant patients 168
Validation and comparison of different PCR-based methods for detection of Hepatitis B virus precore region mutants 168
Uridine diphosphate glucoronosyl transferases, candidate antigens of liver-kidney microsomal antibodies in hepatitis delta virus-infected patients 167
'e' antigen defective hepatitis B virus and course of chronic infection 167
IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? 166
Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care' 166
New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases 166
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 166
Problems in diagnosing viral hepatitis 165
Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences 165
Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders 165
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 165
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 165
Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. 165
An Unexpected Case of Opisthorchis felineus Infection Revealed during Liver Transplantation 164
Potential applications of extracorporeal photopheresis in liver transplantation 164
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. 163
Personalized Therapy in chronic viral hepatitis 163
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 163
Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response 162
Role of hepatitis delta virus infection in hepatocellular carcinoma 162
Comparable function of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors 162
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole 161
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 160
Laparoscopic robot-assisted distal splenorenal shunt 159
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 159
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection 158
Does HBeAg minus HBV modify the course of HDV superinfection? 157
Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis 157
Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders 157
Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. 156
Diagnosis and monitoring of hepatitis virus infection in liver transplant patients 156
AISF position paper on HCV in immunocompromised patients. 156
Different aspects of HDV and HBV reinfections and liver disease in orthotopic liver transplant (OLT) 155
T cell receptor-therapy in HBV-related hepatocellularcarcinoma. 155
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 154
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 153
Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey 153
Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? 151
Diagnostic markers of chronic hepatitis B infection and disease” 151
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases 151
A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS (R)), lamivudine, or PEGASYS (R) plus lamivudine combin 151
Ruolo degli acidi nucleici e marcatori immunologici nella diagnosi e gestione del portatore cronico di virus epatici maggiori (B, C e D) 150
Totale 17.693
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.548
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 162.548
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.379 130 272 73 270 777 677 171 201 245 212 161 1.190
2022/20233.247 615 321 205 252 340 459 41 232 533 24 181 44
2023/20243.413 436 318 378 174 496 817 63 75 79 40 84 453
2024/202511.305 37 506 120 524 545 899 1.060 704 1.231 1.721 1.532 2.426
2025/202614.302 742 2.130 2.048 1.729 1.017 1.385 1.827 658 758 1.193 522 293
2026/2027166 166 0 0 0 0 0 0 0 0 0 0 0
Totale 56.016